The integration of epigenomic profiling in clinical diagnostics may guide the choice of epigenetic therapy – an approach already employed when giving IDH inhibitors to IDH-mutant AML or considering Menin inhibitors for MLL/NPM1 cases. Here, MEN1 is linked to acute myeloid leukemia.